TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03677102

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: higher chloride crystalloid
Description: Normal saline (chloride concentration 154 mmol/L)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower chloride crystalloid
Description: Ringer's Lactate (chloride concentration 110 mmol/L)
Study: NCT03591328

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings.

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings.
Study: NCT01807845

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: enriched skimmilk with VD
Description: enriched skimmilk with VD

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
Description: Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: un-enriched skimmilk.
Description: Placebo: un-enriched skimmilk
Study: NCT02215447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB paclitaxel
Description: 100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT00391521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS703569
Description: Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS703569
Description: Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS703569
Description: Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
Study: NCT02558322

Intervention type: OTHER
Intervention: Primary medical care
Description: All study participants receive primary care as usual in the respective region
Study: NCT03330847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib Continuous (28-Day cycle) 300 mg BD.
Description: Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
Description: Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Description: Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
Study: NCT02856620

Intervention type: OTHER
Intervention: Observational only
Description: Observational only

Intervention type: OTHER
Intervention: Observational only
Description: Observational only

Intervention type: OTHER
Intervention: Observational only
Description: Observational only

Intervention type: OTHER
Intervention: Observational only
Description: Observational only

Intervention type: OTHER
Intervention: Observational only
Description: Observational only

Intervention type: OTHER
Intervention: Observational only
Description: Observational only
Study: NCT00123110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide injection
Description: 3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pill
Description: matching pill twice a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: matching pill twice a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo injection
Description: matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
Study: NCT03455530

Intervention type: OTHER
Group type: OTHER
Intervention: Industrial Hygiene-Enhance Community Health Worker Intervention
Description: The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Industrial Hygiene-Enhance Community Health Worker Intervention
Description: The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
Study: NCT02426294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study: NCT03722849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Triphosphate
Description: Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Triphosphate
Description: Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Brain Imaging
Description: Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Brain Imaging
Description: Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
Study: NCT03155061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: ONO-4578 specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: ONO-4578 specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: ONO-4578 specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: ONO-4578 specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: ONO-4538 specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: ONO-4538 specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: ONO-4538 specified dose on specified days
Study: NCT04253028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NERv's Inline Device
Description: NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
Study: NCT01995058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Tablets taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Tablets taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Tablets taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone
Description: Tablets taken orally daily
Study: NCT02558322

Intervention type: OTHER
Intervention: Primary medical care
Description: All study participants receive primary care as usual in the respective region

Intervention type: OTHER
Intervention: Primary medical care
Description: All study participants receive primary care as usual in the respective region
Study: NCT01995058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Description: Tablets taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Description: Tablets taken orally daily
Study: NCT03383965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICAR30 T cells
Description: T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
Study: NCT05221944

Intervention type: OTHER
Intervention: Patients had a history of antithrombotic therapy
Description: Patients with antithrombotic drugs were identified and grouped and their medical records were reviewed.

Intervention type: OTHER
Intervention: Patients had no history of antithrombotic therapy
Description: Patients had no history of antithrombotic therapy
Study: NCT03717155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m\^2) body surface area on Day 1 and 500 mg/m\^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m\^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m\^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants received cisplatin intravenous infusions at a dose of 75 mg/m\^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.
Study: NCT02716961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, cisplatin
Description: Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
Study: NCT01570790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 phosphate
Description: 27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate
Description: 36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
Study: NCT01995058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Description: Tablets taken orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Tablets taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Tablets taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Tablets taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Tablets taken orally twice daily
Study: NCT03494816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib Oral Tablet
Description: Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.
Study: NCT04819282

Intervention type: DIAGNOSTIC_TEST
Intervention: Senior Fitness Test
Description: Senior Fitness Test, simple and easy to use, was used to evaluate physical performance.
Study: NCT02885974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib (100 mg daily)
Study: NCT00203788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: Supported education/employment
Study: NCT02885974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
Study: NCT01570790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate
Description: 45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
Study: NCT03631706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Study: NCT02795780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: positron emission tomography (PET) scan
Study: NCT03568916

Intervention type: DRUG
Intervention: Apixaban (ATC B01AF02)
Description: Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Intervention type: DRUG
Intervention: Apixaban (ATC B01AF02)
Description: Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Intervention type: DRUG
Intervention: Dabigatran (ATC B01AE07)
Description: Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Intervention type: DRUG
Intervention: Dabigatran (ATC B01AE07)
Description: Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Intervention type: DRUG
Intervention: Rivaroxaban (ATC B01AF01)
Description: Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Study: NCT01900353

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brushing methods

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brushing methods
Study: NCT03637270

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplementation
Description: Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation
Description: Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Including aerobic cycling training and progressive resisted exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Including aerobic cycling training and progressive resisted exercise
Study: NCT00203788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace Fundamentals Module
Description: Group skills training on job/school topics

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brokered Vocational Rehabilitation
Description: Vocational rehabilitation through traditional separate state-funded agency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral risperidone
Description: Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills training group
Description: Group social skills training that did not focus primarily on work situations
Study: NCT03631706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Study: NCT02510443

Intervention type: DEVICE
Intervention: ESS305 (Essure, BAY1454032)
Description: Bilateral insert placement
Study: NCT01656460

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation Arm 1
Description: Dose Levels Dose per Fraction Total Dose~1 8 Gy 16 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation Arm 2
Description: Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation Arm 3
Description: Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation Arm 4
Description: Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
Study: NCT04148326

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study: NCT03566199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat Nanoparticle Formulation MTX110
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convection-Enhanced Delivery (CED)
Description: Undergo CED
Study: NCT00556296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRP104
Description: NRP104 30mg capsule once daily in a.m.
Study: NCT03568916

Intervention type: DRUG
Intervention: Rivaroxaban (ATC B01AF01)
Description: Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.